2. Academic Validation
  3. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

  • Mol Cancer Ther. 2017 Dec;16(12):2677-2688. doi: 10.1158/1535-7163.MCT-16-0674.
Genshi Zhao 1,  Colin F Green 2,  Yu-Hua Hui 3,  Lourdes Prieto 4,  Robert Shepard 5,  Sucai Dong 5,  Tao Wang 5,  Bo Tan 2,  Xueqian Gong 5,  Lisa Kays 5,  Robert L Johnson 2,  Wenjuan Wu 5,  Shobha Bhattachar 6,  Miriam Del Prado 4,  James R Gillig 4,  Maria-Carmen Fernandez 4,  Ken D Roth 4,  Sean Buchanan 5,  Ming-Shang Kuo 4,  Sandaruwan Geeganage 5,  Timothy P Burkholder 4
Affiliations

Affiliations

  • 1 Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Zhao_Genshi@Lilly.com.
  • 2 Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • 3 Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • 4 Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • 5 Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • 6 Product Design and Developability, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
PMID: 29054982 DOI: 10.1158/1535-7163.MCT-16-0674
Abstract

NAMPT, an Enzyme essential for NAD+ biosynthesis, has been extensively studied as an Anticancer target for developing potential novel therapeutics. Several NAMPT inhibitors have been discovered, some of which have been subjected to clinical investigations. Yet, the on-target hematological and retinal toxicities have hampered their clinical development. In this study, we report the discovery of a unique NAMPT Inhibitor, LSN3154567. This molecule is highly selective and has a potent and broad spectrum of Anticancer activity. Its inhibitory activity can be rescued with nicotinic acid (NA) against the cell lines proficient, but not those deficient in NAPRT1, essential for converting NA to NAD+ LSN3154567 also exhibits robust efficacy in multiple tumor models deficient in NAPRT1. Importantly, this molecule when coadministered with NA does not cause observable retinal and hematological toxicities in the rodents, yet still retains robust efficacy. Thus, LSN3154567 has the potential to be further developed clinically into a novel Cancer therapeutic. Mol Cancer Ther; 16(12); 2677-88. ©2017 AACR.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12971
    99.48%, NAMPT抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z